Pharmacovigilance: empowering healthcare professionals and patients
- 460 Downloads
The European Union has thoroughly reformed its pharmacovigilance legislation in July 2012. Despite the changes, underreporting of adverse drug reactions remains a concern. This underreporting seems to be partially associated with incorrect customs and beliefs by healthcare professionals. Therefore, strengthening teaching and training in drug safety monitoring and reporting are essential. Sustained campaigns and education on pharmacovigilance are key elements to enhance its performance and effectiveness. In general, all healthcare professionals as well as patients should be more sensitized and empowered to contribute to pharmacovigilance programmes in order to improve drug safety.
KeywordsAdverse drug reaction Drug safety Health care professional Patient Pharmacovigilance Spontaneous reporting
We thank the European Society of Clinical Pharmacy (ESCP) for having supported the workshop “Adverse Drug Reactions—Applying Theory to Practice” at the 41st ESCP Symposium in October 2012. We are also grateful to the participants of the workshop for completing the survey.
Conflicts of interest
- 1.Anonymous. European medicines agency. New EU pharmacovigilance legislation—key concepts. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/07/WC500129593.pdf Accessed 16 Aug 2013.
- 7.González-Rubio F, Calderón-Larrañaga A, Poblador-Plou B, Navarro-Pemán C, López-Cabañas A, Prados-Torres A. Underreporting of recognized adverse drug reactions by primary care physicians: an exploratory study. Pharmacoepidemiol Drug Saf. 2011;20(12):1287–94. doi: 10.1002/pds.2172.PubMedCrossRefGoogle Scholar
- 8.Avery AJ, Anderson C, Bond CM, Fortnum H, Gifford A, Hannaford PC, et al. Evaluation of patient reporting of adverse drug reactions to the UK ‘Yellow Card Scheme’: literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol Assess. 2011;15(20):1–234. doi: 10.3310/hta15200.PubMedGoogle Scholar
- 11.Rolfes L, Wilkes S, van Hunsel F, van Puijenbroek E, van Grootheest K. Important information regarding reporting of adverse drug reactions: a qualitative study. Int J Pharm Pract. 2013. doi: 10.1111/ijpp.12056.
- 12.Durrieu G, Palmaro A, Pourcel L, Caillet C, Faucher A, Jacquet A, et al. First French experience of ADR reporting by patients after a mass immunization campaign with Influenza A (H1N1) pandemic vaccines: a comparison of reports submitted by patients and healthcare professionals. Drug Saf. 2012;35(10):845–54. doi: 10.2165/11631800-000000000-00000.PubMedCrossRefGoogle Scholar
- 14.Marques J, Ribeiro-Vaz I, Pereira AC, Polónia J. A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal. Int J Pharm Pract. 2014;22(4):275–82. doi: 10.1111/ijpp.12078.
- 19.White RW, Harpaz R, Shah NH, DuMouchel W, Horvitz E. Toward enhanced pharmacovigilance using patient-generated data on the internet. Clin Pharmacol Ther. 2014;96(2):239–46. doi: 10.1038/clpt.2014.77.